Jazz Pharmaceuticals (JAZZ) Long-Term Investments (2014 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Long-Term Investments of $1.0 billion for Q1 2026, up 45.07% year-over-year from $710.0 million in Q1 2025, and down 1.9% quarter-over-quarter from $1.0 billion in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Long-Term Investments (2014 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Long-Term Investments history runs 12 years deep, the most recent figure standing at $1.0 billion for Q1 2026.
- In Q1 2026, Long-Term Investments rose 45.07% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (up 45.07% YoY), while the FY2025 annual figure was $1.0 billion, up 81.03% from the prior year.
- Long-Term Investments for Q1 2026 stood at $1.0 billion, down from $1.0 billion in the prior quarter.
- The five-year high for Long-Term Investments was $1.0 billion in Q4 2025, with the low at $60.0 million in Q2 2022.
- The 5-year median for Long-Term Investments is $440.0 million (2024), against an average of $467.1 million.
- The sharpest annual moves came in 2024 and 2025: Long-Term Investments surged 681.25% in 2024, then decreased 23.2% in 2025.
- Jazz Pharmaceuticals' Long-Term Investments stood at $60.0 million in 2022, then surged by 100.0% to $120.0 million in 2023, then jumped by 383.33% to $580.0 million in 2024, then surged by 81.03% to $1.0 billion in 2025, then declined by 1.9% to $1.0 billion in 2026.
- Business Quant data shows JAZZ's Long-Term Investments at $1.0 billion in Q1 2026, $1.0 billion in Q4 2025, and $720.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 580.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 580.00 Mn |
| Mar 31, 2026 | 1.03 Bn |
| Dec 31, 2025 | 1.05 Bn |
| Sep 30, 2025 | 720.00 Mn |
| Jun 30, 2025 | 480.00 Mn |
| Mar 31, 2025 | 710.00 Mn |
| Dec 31, 2024 | 580.00 Mn |
| Sep 30, 2024 | 400.00 Mn |
| Jun 30, 2024 | 625.00 Mn |
| Mar 31, 2024 | 375.00 Mn |
| Dec 31, 2023 | 120.00 Mn |
| Sep 30, 2023 | 250.00 Mn |
| Jun 30, 2023 | 80.00 Mn |
| Sep 30, 2022 | 60.00 Mn |
| Jun 30, 2022 | 60.00 Mn |
| Mar 31, 2021 | 335.00 Mn |
| Dec 31, 2020 | 1.08 Bn |
| Sep 30, 2020 | 1.18 Bn |
| Jun 30, 2020 | 910.00 Mn |
| Mar 31, 2020 | 280.00 Mn |